Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a global medical technology company whose news flow reflects its activity across anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. Company announcements frequently highlight portfolio developments, clinical research, financial performance, and governance changes, giving investors and healthcare professionals insight into how the business is evolving.
Recent Teleflex news has included leadership transitions, with the Board appointing a long-serving director as Interim President and Chief Executive Officer and naming a new Chair of the Board, as well as updates on the search for a permanent CEO. The company has also reported on strategic portfolio actions, such as agreements to sell its Original Equipment Manufacturing and Development Services business and its acute care and interventional urology segments, reflecting a shift toward a more focused organization centered on core critical care and high-acuity hospital markets.
On the operational side, Teleflex regularly issues quarterly earnings releases and outlook updates, detailing revenue by region and global product category, along with commentary on non-GAAP measures like adjusted revenue and adjusted constant currency revenue growth. Dividend declarations and share repurchase authorizations are also communicated through press releases and associated SEC filings.
For those following clinical and product developments, Teleflex news covers topics such as the launch of the Barrigel™ rectal spacer in new markets and support for investigator-initiated trials like the DUBSTENT DIABETES study in interventional cardiology. Visitors to this TFX news page can review these updates in one place to understand how Teleflex’s strategy, portfolio, and financial profile are changing over time.
Teleflex (NYSE: TFX) has released its 2024 Global Impact Report, detailing the company's Corporate Social Responsibility (CSR) achievements and future objectives. The report adheres to GRI, SASB, and TCFD standards, focusing on four key pillars: Community & Sustainable Healthcare, Planet & Environment, People, and Ethics & Governance.
Key highlights include: completion of a double materiality assessment aligned with E.U. Corporate Sustainability Reporting Directive, signing the World Economic Forum Zero Health Gaps Pledge for equitable healthcare access, submission of CDP Climate Questionnaire tracking greenhouse gas emissions since 2019, and maintaining ISO 14001 certification across 6 facilities.
Teleflex (NYSE:TFX) has announced a quarterly cash dividend of $0.34 per share of common stock. The dividend will be paid on June 16, 2025, to shareholders who are on record as of the close of business on May 20, 2025. This dividend declaration demonstrates the company's commitment to returning value to shareholders through regular cash distributions.
Teleflex (NYSE: TFX) has announced its participation in the upcoming BofA Securities 2025 Health Care Conference. The company's management will deliver a presentation at the Encore Hotel in Las Vegas, Nevada, on Wednesday, May 14, 2025, at 1:40 p.m. Pacific Time.
Investors and interested parties can access a live audio webcast of the presentation through the investor section of Teleflex's website at teleflex.com. This healthcare conference appearance represents an opportunity for Teleflex to engage with industry stakeholders and share company updates.
Teleflex has received FDA 510(k) clearance for expanded indications of its QuikClot Control+™ Hemostatic Device, now approved for all grades of internal and external bleeding. This expansion significantly broadens the device's applications beyond its previous indications for specific surgical procedures and bleeding types.
The clearance was supported by real-world evidence from a study of 603 emergency, trauma, and surgical patients across multiple U.S. sites. The expanded indication is expected to add over $150 million to Teleflex's serviceable addressable market in the United States.
The device can now be used for temporary control of external and internal bleeding ranging from mild to life-threatening cases. Already commercialized in the European Union in 2024, this development allows Teleflex to target additional procedures in trauma, general surgery, gynecologic surgery, and orthopedic surgery, potentially improving clinical and economic outcomes.
Teleflex (NYSE:TFX) has announced multiple clinical studies and educational sessions to be presented at the 2025 American Urological Association Annual Meeting in Las Vegas from April 26-29, 2025.
The presentations will focus on clinical and real-world evidence supporting innovations in benign prostatic hyperplasia (BPH) treatment and rectal spacing for prostate cancer radiation treatment. Key studies include the CLEAR Randomized Controlled Trial comparing UroLift™ PUL versus Rezum WVTT, the IMPACT trial evaluating UroLift™ PUL versus medication, and research on the safety of stabilized hyaluronic acid as a rectal spacer.
The company will host several educational events, including a Semi-Live Barrigel Case Review, an APP educational breakfast on efficient urology practice, and a Prostate Health Symposium at Allegiant Stadium. Daily presentations will also take place at Teleflex booth 1401, featuring discussions on both the Barrigel™ rectal spacer and UroLift™ System.